Related Experiment Videos
Management of Behçet's disease
Fatma Alibaz-Oner1, Amr H Sawalha2, Haner Direskeneli1
1Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey.
Current Opinion in Rheumatology
|February 13, 2018
Summary
New studies show promising treatments for Behçet
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Behçet's disease is a rare multisystem inflammatory disorder.
- Refractory mucocutaneous and major organ involvement pose significant treatment challenges.
Purpose of the Study:
- To summarize current treatment modalities for Behçet's disease.
- To review recent studies (last 2 years) on novel therapeutic approaches.
Main Methods:
- Literature review of studies published within the last two years.
- Analysis of data on efficacy and safety of emerging treatments.
Main Results:
- Apremilast, anakinra, and ustekinumab show promise for refractory mucocutaneous symptoms.
- Tumor necrosis factor-α inhibitors and interferon-α are effective for major organ involvement.
- Interleukin-1 inhibitors and tocilizumab are potential options for refractory ocular disease.
Conclusions:
- Recent advancements offer new hope for managing refractory Behçet's disease.
- Further prospective studies are needed to confirm efficacy and safety.